Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment

Proceedings from the 5th International Post-ASH Symposium

Ayalew Tefferi, O. Abdel-Wahab, F. C. Ervantes, J. D. Crispino, G. Finazzi, F. Girodon, H. Gisslinger, J. Gotlib, J. J. Kiladjian, R. L. Levine, J. D. Licht, A. Mullally, O. Odenike, Animesh D Pardanani, R. T. Silver, E. Solary, T. Mughal

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCRABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7-8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presented at the 2010 ASH meeting, were discussed among recognized authorities in the field. The current paper summarizes the proceedings of this meeting in BCR-ABL1-negative MPN. We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inhibitors, pomalidomide, everolimus, interferon-a, midostaurin and cladribine. In addition, the new 'Dynamic International Prognostic Scoring System (DIPSS)-plus' prognostic model for primary myelofibrosis (PMF) and the clinical relevance of distinguishing essential thrombocythemia from prefibrotic PMF are discussed.

Original languageEnglish (US)
Article numbere7
JournalBlood Cancer Journal
Volume1
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Primary Myelofibrosis
4'-N-benzoylstaurosporine
Hematology
Epigenomics
Cladribine
Janus Kinases
Essential Thrombocythemia
Isocitrate Dehydrogenase
Comb and Wattles
Mutation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogenes
Interferons
Neoplasms
Research
Enhancer of Zeste Homolog 2 Protein
pomalidomide
Everolimus

Keywords

  • Mastocytosis
  • Myelofibrosis
  • Myeloproliferative
  • Polycythemia
  • Thrombocythemia

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment : Proceedings from the 5th International Post-ASH Symposium. / Tefferi, Ayalew; Abdel-Wahab, O.; Ervantes, F. C.; Crispino, J. D.; Finazzi, G.; Girodon, F.; Gisslinger, H.; Gotlib, J.; Kiladjian, J. J.; Levine, R. L.; Licht, J. D.; Mullally, A.; Odenike, O.; Pardanani, Animesh D; Silver, R. T.; Solary, E.; Mughal, T.

In: Blood Cancer Journal, Vol. 1, No. 3, e7, 03.2011.

Research output: Contribution to journalArticle

Tefferi, A, Abdel-Wahab, O, Ervantes, FC, Crispino, JD, Finazzi, G, Girodon, F, Gisslinger, H, Gotlib, J, Kiladjian, JJ, Levine, RL, Licht, JD, Mullally, A, Odenike, O, Pardanani, AD, Silver, RT, Solary, E & Mughal, T 2011, 'Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium', Blood Cancer Journal, vol. 1, no. 3, e7. https://doi.org/10.1038/bcj.2011.4
Tefferi, Ayalew ; Abdel-Wahab, O. ; Ervantes, F. C. ; Crispino, J. D. ; Finazzi, G. ; Girodon, F. ; Gisslinger, H. ; Gotlib, J. ; Kiladjian, J. J. ; Levine, R. L. ; Licht, J. D. ; Mullally, A. ; Odenike, O. ; Pardanani, Animesh D ; Silver, R. T. ; Solary, E. ; Mughal, T. / Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment : Proceedings from the 5th International Post-ASH Symposium. In: Blood Cancer Journal. 2011 ; Vol. 1, No. 3.
@article{6fe21e4a497146d3ac1a090200a9ec30,
title = "Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium",
abstract = "Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCRABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7-8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presented at the 2010 ASH meeting, were discussed among recognized authorities in the field. The current paper summarizes the proceedings of this meeting in BCR-ABL1-negative MPN. We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inhibitors, pomalidomide, everolimus, interferon-a, midostaurin and cladribine. In addition, the new 'Dynamic International Prognostic Scoring System (DIPSS)-plus' prognostic model for primary myelofibrosis (PMF) and the clinical relevance of distinguishing essential thrombocythemia from prefibrotic PMF are discussed.",
keywords = "Mastocytosis, Myelofibrosis, Myeloproliferative, Polycythemia, Thrombocythemia",
author = "Ayalew Tefferi and O. Abdel-Wahab and Ervantes, {F. C.} and Crispino, {J. D.} and G. Finazzi and F. Girodon and H. Gisslinger and J. Gotlib and Kiladjian, {J. J.} and Levine, {R. L.} and Licht, {J. D.} and A. Mullally and O. Odenike and Pardanani, {Animesh D} and Silver, {R. T.} and E. Solary and T. Mughal",
year = "2011",
month = "3",
doi = "10.1038/bcj.2011.4",
language = "English (US)",
volume = "1",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment

T2 - Proceedings from the 5th International Post-ASH Symposium

AU - Tefferi, Ayalew

AU - Abdel-Wahab, O.

AU - Ervantes, F. C.

AU - Crispino, J. D.

AU - Finazzi, G.

AU - Girodon, F.

AU - Gisslinger, H.

AU - Gotlib, J.

AU - Kiladjian, J. J.

AU - Levine, R. L.

AU - Licht, J. D.

AU - Mullally, A.

AU - Odenike, O.

AU - Pardanani, Animesh D

AU - Silver, R. T.

AU - Solary, E.

AU - Mughal, T.

PY - 2011/3

Y1 - 2011/3

N2 - Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCRABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7-8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presented at the 2010 ASH meeting, were discussed among recognized authorities in the field. The current paper summarizes the proceedings of this meeting in BCR-ABL1-negative MPN. We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inhibitors, pomalidomide, everolimus, interferon-a, midostaurin and cladribine. In addition, the new 'Dynamic International Prognostic Scoring System (DIPSS)-plus' prognostic model for primary myelofibrosis (PMF) and the clinical relevance of distinguishing essential thrombocythemia from prefibrotic PMF are discussed.

AB - Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCRABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7-8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presented at the 2010 ASH meeting, were discussed among recognized authorities in the field. The current paper summarizes the proceedings of this meeting in BCR-ABL1-negative MPN. We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inhibitors, pomalidomide, everolimus, interferon-a, midostaurin and cladribine. In addition, the new 'Dynamic International Prognostic Scoring System (DIPSS)-plus' prognostic model for primary myelofibrosis (PMF) and the clinical relevance of distinguishing essential thrombocythemia from prefibrotic PMF are discussed.

KW - Mastocytosis

KW - Myelofibrosis

KW - Myeloproliferative

KW - Polycythemia

KW - Thrombocythemia

UR - http://www.scopus.com/inward/record.url?scp=84859306234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859306234&partnerID=8YFLogxK

U2 - 10.1038/bcj.2011.4

DO - 10.1038/bcj.2011.4

M3 - Article

VL - 1

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 3

M1 - e7

ER -